Bayer stresses drug's tolerability in bid for prostate cancer market

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 15, 2019 at 10:32 AM.

  1. #1 cafead, Feb 15, 2019 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.

    article source
     
    Quote

Reply to Thread